skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

​Complete drug tracking

Pharmaprojects | Pharma intelligence

Follow company pipelines in over 40 countries and probe more than 30 years of R&D history to uncover trends that have, and will, impact the drug development industry.

How it works

Pharmaprojects provides comprehensive coverage of drug development, from discovery to end of patent and market exclusivity. Its intuitive search interface supports quick access to disease-, company-, or country-specific drug development results. These can be visualized quickly via an analytic dashboard, or exportable into several formats.

How it can help

Pharmaprojects' expert analysts track in- and out-licensing acitivity making it easy to identify opportunities or market saturation.These analysts will conduct primary research on your behalf to try to uncover additional information around your drug or company of interest.  And, the deep linking to Trialtrove means that you will be on top of any clinical trial developments for your disease, company, or therapeutic mechanism of interest.

What's included

robust curated content  treatment trends analysis pharma intelligence

​Robust, curated content

Analyst reviewed and enriched trial profiles, including tags for key attributes

durgR and DLandscape pipeline pharma intelligence

Drug R&D landscape

Development history, licensing information, molecular structure and more

historical trends indepth analysis pharma intelligence

Historical trends

Attain an analysis of drug development trends from 1995 to date

ask the analyst pharma intelligence

Ask the Analyst

Unlimited research support from experienced industry analysts

dynamic visual results sales forecasts pharma intelligence

Dynamic visual results

Instantly generate tables and charts of key trial counts

Pharmaprojects

  • Clinical trial intelligence

    Pharmaprojects

    AiCuris seeks partners for antibacterial programs

    07 Dec 2016

    AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. Zimmermann highlights AiCuris's anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans. AiCuris already has an exclusive worldwide licensing agreement in place with Merck & Co. for its lead compound, letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of human cytomegalovirus (HCMV) infection in transplant recipients. AiCuris received a EUR 110 million upfront payment from Merck as part of this deal, which covers AiCuris's novel portfolio of investigational HCMV medicines.

  • Clinical trial intelligence

    Pharmaprojects

    BioNTechs Sean Marett explains Genentech deal rationale

    07 Dec 2016

    Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.

  • Clinical trial intelligence

    Pharmaprojects

    Cinfa outlines biosimilar development areas and deal opportunities

    07 Dec 2016

    Cinfa Biotech's managing director, Ruediger Jankowsky, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company's founding and focus on biosimilar drug development. They discuss Cinfa's biosimilars business model, disease areas of focus and potential deals for the company in the near future.

  • Clinical trial intelligence

    Pharmaprojects

    Dimerix CEO explains companys different drug combo R and D strategy

    07 Dec 2016

    Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company's unusual business model. They discuss Dimerix's Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix's pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix's lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.

  • Clinical trial intelligence

    Pharmaprojects

    eTheRNA CEO outlines development plan in cancer RNA space

    07 Dec 2016

    Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe® partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

  • Clinical trial intelligence

    Pharmaprojects

    F star business chief discuss Denali deal and potential F star delta spinout

    07 Dec 2016

    Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star's asset-centric business strategy, the company's recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.

  • Clinical trial intelligence

    Pharmaprojects

    How are regulatory changes affecting early stage R and D in China

    07 Dec 2016

    Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China.  Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.

  • Clinical trial intelligence

    Pharmaprojects

    Novel Biologics for Asthma: Steps on the Long Road to Therapies for Uncontrolled Asthma

    By Laura Runkel 28 Nov 2016

    After many years of research, the first two novel biologics have been filed for approval for uncontrolled, eosinophilic asthma treatment. Will the hope for truly targeted therapies for uncontrolled asthma now be realized? After many years of research, the first two novel biologics have been filed for approval for uncontrolled, eosinophilic asthma treatment. Will the hope for truly targeted therapies for uncontrolled asthma now be realized?

  • Clinical trial intelligence

    Pharmaprojects

    Is Achieving Trial Success a Roll of the Dice?

    28 Nov 2016

    An examination of Autoimmune/Inflammation clinical trial-level success rates

    Topics Clinical trials

  • Clinical trial intelligence

    Pharmaprojects

    The evolution of clinical research in East Asia

    By Roger Longman 25 Nov 2016

    Citeline Doro's analyzes the increased activity of clinical trials located in East Asia.  This report gives a detailed look into characteristics of trials currently being conducted and planned in East Asia.

    Topics Infectious diseases

  • Clinical trial intelligence

    Pharmaprojects

    Announcing the Clinical and Research Excellence Awards and a call for nominations

    25 Jan 2016

    On April 27, 2016, Informa will host its inaugural Clinical and Research Excellence (CARE) Awards to honor those in clinical R&D who are making a difference and committed to making human lives better.

  • Clinical trial intelligence

    Pharmaprojects

    Upcoming Novel HIV Single Tablet Regimens

    01 Dec 2015

    For World AIDS Day, we look at current and upcoming novel single tablet regimens (STRs) for HIV treatment. STR’s primary advantage is that they simplify treatment and this leads to greater patient adherence, lower resistance emergence and overall improved outcomes over more traditional cocktails of antiretroviral drugs

  • Clinical trial intelligence

    Pharmaprojects

    Prostate Cancer Still A Common Occurrence

    24 Nov 2015

    When considering cancer in men, prostate cancer could be described as ‘all too frequent’. Indeed, the annual month of ‘Movember’ is here once again and serves as a stark reminder that men worldwide are still dying too young from this disease.Worldwide prostate cancer is currently the second most common cancer in males and the fourth most common cancer overall, with over 1.1 million new cases diagnosed in 2012

  • Clinical trial intelligence

    Pharmaprojects

    PCSK9 Inhibitors What does the future hold for this controversial new class

    28 Oct 2015

    With the recent launch of Regeneron/Sanofi’s Praluent® and Amgen’s Repatha®, which are both fully human anti-PCSK9 monoclonal antibodies, it is interesting to consider the other molecular approaches being pursued in the burgeoning PCSK9 inhibitor arena.

  • Competitive and market intelligence Regulatory approval Business and portfolio strategy Business development and licensing

    Pharmaprojects

    Anticancer Immunotherapy - A New Weapon Against Cancer

    By Jonathan Stephens 06 Jul 2015

    Since its inception in the mid-20th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective. 

    Topics Immuno-oncology

;

Meet the team

Management

Ian Lloyd

Management, Senior Director

UK

Ian Lloyd

Ian specializes in

  • Commercial Strategy

+29 year(s) experience

Management

Karen Currie

Management, Executive Director, Editorial

USA

Karen Currie

Karen specializes in

  • Commercial Strategy

+27 year(s) experience

Management

Patricia Reilly

Management, Vice President, Intelligence Alliances and Product Unification

USA

Patricia Reilly

Patricia specializes in

  • CNS
  • Immunology & Inflammation
  • Oncology

+25 year(s) experience

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: